MX2024011697A - Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3) - Google Patents
Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)Info
- Publication number
- MX2024011697A MX2024011697A MX2024011697A MX2024011697A MX2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A
- Authority
- MX
- Mexico
- Prior art keywords
- domain
- nlrp3
- pyrido
- nucleotide
- receptor
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000009739 binding Methods 0.000 title 1
- 238000006384 oligomerization reaction Methods 0.000 title 1
- IHYJXEQIZYROGA-UHFFFAOYSA-N pyrido[3,4-d]pyridazine Chemical compound N1=NC=C2C=NC=CC2=C1 IHYJXEQIZYROGA-UHFFFAOYSA-N 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/704,983 US11618751B1 (en) | 2022-03-25 | 2022-03-25 | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US202263420930P | 2022-10-31 | 2022-10-31 | |
| US202363443874P | 2023-02-07 | 2023-02-07 | |
| PCT/US2023/064967 WO2023183943A1 (en) | 2022-03-25 | 2023-03-24 | Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011697A true MX2024011697A (es) | 2024-11-08 |
Family
ID=86329581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011697A MX2024011697A (es) | 2022-03-25 | 2024-09-24 | Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3) |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4499638A1 (https=) |
| JP (1) | JP2025510414A (https=) |
| KR (1) | KR20250005125A (https=) |
| CN (1) | CN119137121A (https=) |
| AU (1) | AU2023238121A1 (https=) |
| CA (1) | CA3246681A1 (https=) |
| CL (1) | CL2024002855A1 (https=) |
| CO (1) | CO2024013702A2 (https=) |
| IL (1) | IL315842A (https=) |
| MX (1) | MX2024011697A (https=) |
| PE (1) | PE20250605A1 (https=) |
| TW (1) | TW202345836A (https=) |
| WO (1) | WO2023183943A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| US12331048B2 (en) * | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| KR20250106322A (ko) * | 2022-12-28 | 2025-07-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도 |
| WO2025059481A1 (en) | 2023-09-13 | 2025-03-20 | Ventus Therapeutics U.S., Inc. | Solid forms of an nlrp3 inhibitor and uses thereof |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US11618751B1 (en) * | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CR20240093A (es) * | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
-
2023
- 2023-03-24 CA CA3246681A patent/CA3246681A1/en active Pending
- 2023-03-24 PE PE2024002059A patent/PE20250605A1/es unknown
- 2023-03-24 WO PCT/US2023/064967 patent/WO2023183943A1/en not_active Ceased
- 2023-03-24 JP JP2025502799A patent/JP2025510414A/ja active Pending
- 2023-03-24 KR KR1020247034096A patent/KR20250005125A/ko active Pending
- 2023-03-24 EP EP23722227.8A patent/EP4499638A1/en active Pending
- 2023-03-24 CN CN202380037553.1A patent/CN119137121A/zh active Pending
- 2023-03-24 TW TW112111280A patent/TW202345836A/zh unknown
- 2023-03-24 AU AU2023238121A patent/AU2023238121A1/en active Pending
- 2023-03-24 IL IL315842A patent/IL315842A/en unknown
-
2024
- 2024-09-24 CL CL2024002855A patent/CL2024002855A1/es unknown
- 2024-09-24 MX MX2024011697A patent/MX2024011697A/es unknown
- 2024-10-10 CO CONC2024/0013702A patent/CO2024013702A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025510414A (ja) | 2025-04-14 |
| IL315842A (en) | 2024-11-01 |
| PE20250605A1 (es) | 2025-02-26 |
| CA3246681A1 (en) | 2023-09-28 |
| CN119137121A (zh) | 2024-12-13 |
| WO2023183943A1 (en) | 2023-09-28 |
| KR20250005125A (ko) | 2025-01-09 |
| TW202345836A (zh) | 2023-12-01 |
| CO2024013702A2 (es) | 2024-11-08 |
| CL2024002855A1 (es) | 2025-02-14 |
| AU2023238121A1 (en) | 2024-10-10 |
| EP4499638A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024011697A (es) | Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3) | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| BR112023021383A2 (pt) | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| CL2024003460A1 (es) | Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos. | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| MX2024014401A (es) | Inhibidor de parp que es un derivado biciclico y uso de este | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| AR126537A1 (es) | Sales y formas en estado sólido de un compuesto inhibidor de kif18a | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| MX2024011179A (es) | Compuestos multiciclicos | |
| UY39799A (es) | Compuestos de pirrolil–sulfonamida | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| UY40772A (es) | Inhibidores de wrn | |
| ECSP034494A (es) | Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| CL2025001819A1 (es) | Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas). | |
| CL2025002150A1 (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR128879A1 (es) | DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3 |